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Quality of lifeAbstract Background: Platinum-based combination chemotherapy is standard treatment for
the majority of patients with advanced non-small-cell lung cancer (NSCLC). The trial inves-
tigates the importance of the choice of platinum agent and dose of cisplatin in relation to pa-
tient outcomes.
Methods: The three-arm randomised phase III trial assigned patients with chemo-naı¨ve stage
IIIB/IV NSCLC in a 1:1:1 ratio to receive gemcitabine 1250 mg/m2 on days 1 and 8 of a 3-
week cycle with cisplatin 80 mg/m2 (GC80) or cisplatin 50 mg/m2 (GC50) or carboplatin
AUC6 (GCb6) for a maximum of four cycles. Primary outcome measure was survival time,
aiming to test for a difference between treatment arms and also assess non-inferiority with
pre-defined margin selected as hazard ratio (HR) of 1.2. Secondary outcome measures
included response rate, adverse events and quality of life (QoL).
Findings: The trial recruited 1363 patients. Survival time differed significantly across the three
treatment arms (p Z 0.046) with GC50 worst with median 8.2 months compared to 9.5 for
GC80 and 10.0 for GCb6. HRs (adjusted) for GC50 compared to GC80 was 1.13 (95% con-
fidence interval [CI] 0.99e1.29) and for GC50 compared to GCb6 was 1.23 (95% CI: 1.08
e1.41). GCb6 was significantly non-inferior to GC80 (HR Z 0.93, upper limit of one-sided
95% CI 1.04). Adjusting for QoL did not change the findings. Best objective response rates
were 29% (GC80), 20% (GC50) and 27% (GCb6), p < 0.007. There were more dose reductions
and treatment delays in the GCb6 arm and more adverse events (60% with at least one grade
3e4 compared to 43% GC80 and 30% GC50).
Interpretation: In combination with gemcitabine, carboplatin at AUC6 is not inferior to
cisplatin at 80 mg/m2 in terms of survival. Carboplatin was associated with more adverse
events and not with better quality of life. Cisplatin at the lower dose of 50 mg/m2 has worse
survival which is not compensated by better quality of life.
ClinicalTrials.gov identifier: NCT00112710.
EudraCT Number: 2004-003868-30.
Cancer Research UK trial identifier: CRUK/04/009.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lung cancer is the leading cause of cancer death
worldwide [1] and is responsible for more than 20% of
cancer deaths in the United Kingdom [2]. Non-small-cell
lung cancer (NSCLC) accounts formore than 80%of lung
cancers and poor outcomes are driven by the fact that the
vast majority present at clinic with advanced disease [3].
This paper reports a large randomised phase III trial in
advanced NSCLC, set up by the British Thoracic
Oncology Group (the BTOG2 trial), to provide definitive
evidence to inform choice of standard first-line treat-
ments. Early presentations of the results from the trial
have already influenced clinical practice and this paper
provides the final conclusive published evidence.
There is continued uncertainty about the optimal
first-line chemotherapy for patients with advanced
NSCLC and hence clinical practice remains variable.
Platinum-based combination chemotherapy was firmly
established following a meta-analysis of eight cisplatin
randomised trials [4] which was later confirmed by an
updated meta-analysis of 16 further trials [5] but there
was ongoing ambiguity about whether cisplatin or car-
boplatin gave better patient outcomes. This was driven
by conflicting trial results, in particular emerging resultsfrom an influential UK trial giving evidence that car-
boplatin with gemcitabine gave better survival than
cisplatin (low dose 50 mg/m2) combined with mitomycin
and ifosfamide [6] and a meta-analysis of five trials
suggesting that in combination with third generation
drugs, such as gemcitabine and taxanes, cisplatin gave
better survival and higher radiological response rates
than carboplatin [7].
In addition, there was uncertainty about the preferred
dose of cisplatin due to a lack of definitive evidence, with
practitioners in the UK more inclined to opt for the
lower dose of 50 mg/m2 every three weeks [6] than
counterparts in Europe and the United States which
considered 75e100 mg/m2 as standard [8,9]. The
cisplatin burden of intravenous hydration and inpatient
administration together with the toxicity of emesis,
neuropathy and perception of poor tolerance led many
clinicians to adopt carboplatin as the preferred option.
Carboplatin however is largely renally cleared and must
be correctly dosed according to glomerular filtration rate
(GFR) [10] and measurement of GFR with 51-Cr-EDTA
is cumbersome and expensive. Even when dosed opti-
mally, carboplatin causes more severe neutropenia and
thrombocytopaenia than cisplatin [11]. The BTOG2 trial
aimed to resolve this cisplatin versus carboplatin debate.
D. Ferry et al. / European Journal of Cancer 83 (2017) 302e312304A large randomised trial in advanced NSCLC in the
USA had shown no differences in response rate or sur-
vival for platinum combinations with gemcitabine,
paclitaxel or docetaxel [8]. At the time of trial set-up, the
most commonly used companion drug for platinum in
the UK was gemcitabine, so this was adopted for the
trial for all types of histology. It was not until 2008 that
evidence arose to show that pemetrexed was a margin-
ally superior companion drug to gemcitabine in non-
squamous NSCLC [12]. However, with the focus of
the BTOG2 trial on platinum choice, the trial remains
relevant for all types of histology. The other key changes
in standard of care is that patients with epidermal
growth factor receptor (EGFR) mutations or anaplastic
lymphoma kinase (ALK) gene rearrangements will
receive tyrosine kinase inhibitors as standard first-line
treatment as per European and USA guidelines [13,14].
However this only affects a very small proportion of all
NSCLC patients in the UK, 8% and 2%, respectively
[15]. Recent results from a phase III trial [16] have lead
to the additional option of an immune-checkpoint in-
hibitor in the first-line setting for a limited number
(likely to be around 15% in real world practice) of pa-
tients with high PD-L1 expression. Thus platinum-based
chemotherapy remains the standard of care and our trial
results remain relevant for the majority of patients.
This paper reports the final results from the BTOG2
trial, which evaluates two doses of cisplatin compared
with carboplatin in combination with gemcitabine as
first-line treatment for advanced NSCLC to determine
which gives the most benefit to patients. The trial has the
major added strength of assessing long-term quality of
life alongside survival in all participants.2. Methods
2.1. Study design
BTOG2 was a three-arm randomised phase III clinical
trial recruiting patients from 78 hospitals in the United
Kingdom and Ireland. Ethics approval for the trial
protocol (ultimately Version 4) was obtained from West
Midlands Research Ethics Committee and local insti-
tutional review boards and ethical committees in
accordance with national and international guidelines.2.2. Patients
Eligible patients had histologically or cytologically
confirmed NSCLC with radiologically verified stage
IIIB/IV disease not amenable to potentially curative
treatment, with no clinically apparent brain metastases.
Patients had no known concomitant or previous ma-
lignancy likely to interfere with protocol treatment or
trial evaluations and no prior chemotherapy or radio-
therapy. They were at least 18 years old with a WorldHealth Organization performance status (PS) score of
0e2 and life expectancy of >12 weeks, adequate organ
and haematologic function and no severe acute or
chronic medical condition that would have impaired the
ability to participate in the study or the interpretation of
results. Pregnant and breast-feeding women were
excluded and those with reproductive potential were
required to use effective methods of contraception. All
patients gave written informed consent.
2.3. Randomisation and masking
Eligible patients were randomly assigned 1:1:1 to receive
gemcitabine 1250 mg/m2 days 1 and 8 of a 3-week cycle
plus on day 1 cisplatin 80 mg/m2 (GC80) or cisplatin
50 mg/m2 (GC50) or carboplatin AUC6 (GCb6) for a
maximum of four cycles. Treatment allocation was by
telephone to the central randomisation service at the
Cancer Research UK Clinical Trials Unit at University
of Birmingham. Randomisation was stratified by stage
of disease (IIIB versus IV) and PS (0 versus 1 versus 2)
and balanced within treatment centres. Treatment was
allocated to patients sequentially using an in-house
validated minimisation algorithm.
2.4. Procedures
Protocol drugs were delivered intravenously either as
inpatient or outpatient, according to local practice. The
estimate of GFR used in the Calvert formula, both for
carboplatin dosing and to determine eligibility (creati-
nine clearance >60 mL/min), used the Wright equation
(the version with creatinine kinase correction and either
enzymatic or Jaffe serum creatinine measurement)
which is equivalent to 51-Cr-EDTA clearance [17]. To
ensure correct dosing we provided an Excel spreadsheet
calculator (Supplementary Material Appendix 1). Also
to ensure optimal and pragmatic hydration for cisplatin
patients, all participating centres complied with the
BTOG2 recommended schedule (Supplementary
Material Appendix 2). Dose adjustments and cycle de-
lays (up to 3 weeks) were permitted in the event of
toxicity with protocol-specific recommendations. Pa-
tients were to be treated for four cycles or until disease
progression or unacceptable toxicity as per physician
judgement. Standard anti-emetics were 5 d of a 5-HT3
antagonist plus dexamethasone 4 mg twice daily or,
after day 8 gemcitabine, oral domperidone 20 mg up to
four times daily as required.
Pre-treatment evaluation included: medical history
(including cancer history and prior anti-cancer treat-
ments), clinical examination (including PS, blood pres-
sure, ECG), laboratory analyses (complete blood count
and coagulation tests, blood chemistry, creatinine
clearance with Wright equation) and tumour assessment
by appropriate imaging techniques with measurable le-
sions being a requirement for the trial. Computed
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cycles (6 weeks), four cycles (12 weeks) and where
possible was repeated at time of withdrawing from
treatment. Response was assessed with Response Eval-
uation Criteria in Solid Tumours (RECIST) 1.0 [18]
locally but there was no requirement for confirmation
of response. Patients had chest x-rays during treatment
and follow-up in accordance with local practice.
Adverse events according to National Cancer Institute-
Common Terminology Criteria for Adverse Events
(NCI-CTCAE) version 3.0 [19] were recorded at every
clinic visit. Follow-up data were collected at standard
post-treatment clinic visits at approximately monthly
intervals. Quality of life questionnaires were adminis-
tered by research nurses prior to randomisation and on
day 1 of each treatment cycle prior to receiving treat-
ment and at every follow-up visit (typically monthly).
They were completed independently by patients.
2.5. Outcomes
The primary outcome was survival time measured in
whole days from randomisation to death from any cause,
with censoring at date of last follow-up for those with no
death date at time of database lock (28th May 2014).
Quality of life was an important secondary outcome
measure. Eligibility criteria required the patient to be
willing and able to complete quality of life questionnaires
which included three validated instruments: the generic
and lung cancer instruments developed by the European
Organisation for Research and Treatment of Cancer
EORTC QLQ-C30 [20] and QLQ-LC13 [21] and the
standardised instrument tomeasure utilities developed by
the EuroQol Group, EQ-5D [22]. Other secondary
outcome measures included: best overall response (based
on RECIST 1.0) [18]; dose intensity of chemotherapy
(calculated for each drug as the mean of dose intensities
for each cycle received, given by actual versus expected
dose per day); proportion of cycles given as an outpatient;
incidence of adverse events (graded2 according toNCI-
CTCAE version 3.0) [19] and costs and cost-effectiveness
(to be reported in a separate paper).
2.6. Statistical analysis
The survivor function for each treatment arm is estimated
using KaplaneMeier method from which medians and 1-
year rates are reported with Greenwood’s formula used
for 95% confidence intervals (CIs). All treatment arms
could be considered ‘standard practice’ so the primary
analysis tests the null hypothesis of no difference between
the three treatment arms initially using a log-rank test as
specified in the protocol but supplemented by Cox
regressionmodel that accounts for stratification factors of
stage and PS as the more recently preferred analytical
approach [23]. Regression coefficients from the model
provide estimates of hazard ratios (HR) with two-sided95% CIs to compare treatment arms. As planned, the
analysis also tests for non-inferiority between treatment
arms, permissible under the closed test procedure [24],
using one-sided 95% CI for HRs with non-inferiority
inferred when the entire CI falls within the non-
inferiority region pre-defined by a margin for the HR of
1.2. All analyses of the primary outcome measure were
based on an intention-to-treat (ITT) principle.
At the design stage, sample size calculations were
based on the primary outcome measure of survival time.
For a log-rank test comparing three treatment arms, 400
deaths were required per arm to enable a difference in
median survival of 2 months (7 versus 9) to be detected
between any of the three arms with 90% power. This is
equivalent to an absolute difference in 1-year survival
rates of the order of 35% versus 45% and an HR of 0.78.
Assuming an accrual period of 3 years and follow-up
period of 1 year, it was estimated that 450 patients per
arm would be need to achieve the required number of
events giving total target recruitment of 1350. With 400
deaths per arm and using a one-sided 95% CI there is
80% power to detect non-inferiority based on a pre-
defined non-inferiority margin for the HR of 1.2 or
absolute difference in median survival of 6 weeks.
Detailed analysis of the longitudinal quality of life
(QoL) data will be reported in a separate paper but
quality-adjusted survival time is reported here using a
method called the integrated quality-survival product
[25]. Survival time, represented by the KaplaneMeier
function, is adjusted for QoL using a step function of the
utility measure from EQ-5D, representing the mean of
all responses from participants still alive at each point
across time. The analysis is based on ITT and restricted
to 12 months from trial entry.
Objective response rates are compared using an ITT
analysis and chi-square test. Analysis of the remaining
secondary outcome measures was based on the per-
protocol population defined as those who received at
least one cycle of their assigned treatment. Dose in-
tensity for platinum and gemcitabine are compared
using one-way analysis of variance. Proportion of
chemotherapy delivery days as an outpatient rather than
inpatient are compared using a chi-square test. Inci-
dence of each type of adverse event is reported
descriptively with a chi-square test pre-selected in the
statistical analysis plan to compare incidence of at least
one grade 3 or 4 adverse event during treatment.
An independent Data Monitoring Committee
reviewed interim data annually to ensure patient safety.
There were no formal stopping rules. The trial was
registered on the EU Clinical Trials Register with
EudraCT number 2004-003868-30.
2.7. Role of the funding source
The trial was sponsored by University of Birmingham
and run by the Cancer Research UK Clinical Trials Unit
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supplemented by an educational grant from Eli Lilly
and Company Ltd. The trial was initiated and con-
ducted independently by the trial investigators. The
funder had no role in trial design, data collection, data
analysis, data interpretation or writing of the report.
The corresponding author had full access to all the data
in the trial and had final responsibility for the decision
to submit for publication.
3. Results
Between April 2005 and November 2009, 1363 patients
were randomised, 456 to GC80, 454 to GC50 and 453 to
GCb6 (Fig. 1). Patient characteristics and disease his-
tory at baseline were well balanced across the treatment
arms (Table 1). The median age for patients in the trial
was 63 years (range 29e83) with predominance of males
(62%) and PS 1 (60%) but also including 8% PS 2. Stage
IV disease was most common (68%) with 38% having
adenocarcinoma histology, 35% squamous cell, 3% large
cell and the remaining 23% unspecified. Post-
randomisation, 16 patients were found to be ineligible
with the most common reason being biochemical mea-
sures found to be marginally outside of the required
range, but half received protocol treatment and all are
included in the ITT analysis.
Treatment delivery details within each of the treat-
ment arms is summarised in Fig. 1. The majority of
patients (62%) received the planned four cycles of1363 eligible patients from 78 centres in UK a
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Fig. 1. : Trial profile. aMultiple reasons were recorded and frequencies r
non-haematological or symptomatic grade 4 haematological; cdied witreatment and this was balanced across treatment arms.
39 patients (2.9%) did not start treatment due to clinical
deterioration. The most common reason for early
withdrawal from treatment in all arms is tumour pro-
gression or stable disease. Grade 3 or 4 non-haemato-
logical toxicity and general intolerable side-effects from
treatment was most common in GC80. Symptomatic
grade 4 haematological toxicity was most common in
GCb6. Across cycles, dose reductions and cycle delays
occurred most in GCb6 and least in GC50
(Supplementary Material Appendix 3) which translated
into a significant difference in dose intensity of platinum
and gemcitabine across treatment arms (Table 2;
p < 0.0001 for both). Dose intensity was lowest for
GCb6 but medians on all treatment arms were at least
80%. Dosing of carboplatin used the Wright equation
which gave prescribed doses on average 10% more
(interquartile range 4%e17% and range 14% to 51%)
than the CockcrofteGault formula (Supplementary
Material Appendix 4).
The incidence of key adverse events at grades 2e4 are
shown in Table 3. Of the total 6802 events reported
across the 4284 patient-cycles received, the majority
(77%) were grade 2, 15% grade 3 and 4% grade 4 (3%
unspecified grade). Hearing loss and tinnitus were pre-
dominantly reported for GC80 but at a low rate with
patient-cycle incidence rate of 7% and only 2% reported
as grade 3 or 4. As expected, rates of nausea and vom-
iting were higher in GC80 compared to GC50 but ab-
solute differences were small in levels of grade 3e4nd Ireland 
consultants
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 allocated 
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Table 1
Baseline patient and disease characteristics.
Characteristic GC80
(N Z 456)
GC50
(N Z 454)
GCb6
(N Z 453)
Male 286 (63%) 291 (64%) 268 (59%)
Female 170 (37%) 163 (36%) 185 (41%)
Age
Median 63 63 63
IQ range 57.5e68 57e69 57e68
Range 30e79 32e82 29e83
Stagea
IIIB 146 (32%) 145 (32%) 144 (32%)
IV 310 (68%) 309 (68%) 309 (68%)
WHO PSa
0 146 (32%) 146 (32%) 145 (32%)
1 275 (60%) 274 (60%) 274 (60%)
2 35 (8%) 34 (8%) 34 (8%)
Prior surgery
No 427 (97%) 416 (95%) 412 (95%)
Yes 15 (3%) 20 (5%) 23 (5%)
Not reported 14 18 18
Histology
Squamous 149 (33%) 152 (33%) 156 (34%)
Adenocarcinoma 169 (37%) 156 (34%) 182 (40%)
Large cell 14 (3%) 12 (3%) 13 (3%)
Unspecified 124 (27%) 134 (30%) 102 (23%)
BSA
N 440 440 441
Median 1.82 1.84 1.82
IQ range 1.68e1.98 1.67e1.97 1.67e1.98
Range 1.35e2.26 1.26e2.45 1.28e2.49
Target lesion size (mm)
N 425 421 430
Median 82 82 83
IQ range 57e117 52e125 56e121
Range 4e553 5e389 10e420
WHO PS, World Health Organization performance status; IQ, inter-
quartile; BSA, body surface area.
a Indicates stratification factors.
Table 2
Comparison of secondary outcome measures across treatment arms.
Secondary outcome measure GC80
Best overall response rate
Number (%) of patients with reported CR or PR 132/456 (29%
Dose intensity for platinum
N 423
Median 94%
Interquartile range 81%e99%
Range 22%e116%
Number (%) of patients 90% 256 (61%)
Dose intensity for gemcitabine
N 419
Median 87%
Interquartile range 74e98%
Range 40e116%
Number (%) of patients 90% 192 (46%)
Proportion of chemotherapy delivery days as an outpatient
N 441
Median 87.5%
Number (%) of patients 100% 207 (47%)
Adverse events
Number (%) of patients with at least 1 grade 3 or 4
adverse event reported during treatment
190/441 (43%
CR, complete response; PR, partial response.
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vomiting). GCb6 was associated with the highest rates
of myelosuppression but with low rates for grade 3e4;
anaemia 4%, neutropenia 16% and thrombocytopaenia
10%. Fatigue was no different between GC80 and GCb6
with grade 3e4 patient-cycle incidence rates of 3.7%
versus 3.4%, respectively. Documented infections
occurred at a similar low rate on the three arms. Overall,
the patient incidence rates for at least one reported
grade 3 or 4 adverse event differed significantly across
the three treatment arms (Table 2; p < 0.0001) with
greatest of 60% on GCb6 compared with 30% on GC50.
The proportion of patients treated in the outpatient
setting is significantly greater for GCb6 (Table 2;
p < 0.0001) with 64% of patients receiving all their cy-
cles as an outpatient compared to only 47% of patients
on GC80. Best response rate to treatment significantly
differed between the three treatment arms (p Z 0.007;
Table 2) with comparable rates for GC80 (29%) and
GCb6 (27%) and a lower rate for GC50 (20%).
At the time of data lock (28th May 2014) there were
1306 deaths. Of the 57 patients still alive, median follow-
up timewas 29monthswithmaximumof 80 and including
5 patients lost to follow-up within 12 months of entry.
Eleven patients diedwithin 28 dof randomisationwithout
starting treatment and 80 patients died during treatment
i.e. within 28 d of day 1 of their last cycle of chemotherapy
(29, 31 and 20 on GC80, GC50 and GCb6, respectively).
KaplaneMeier estimates of survival (Fig. 2A, Table 4)
show that GC50 had the worst survival time with median
8.2monthswhilstGC80 andGCb6were comparablewith
medians of 9.5 and 10.0 months, respectively. This dif-
ference between treatment arms was statistically signifi-
cant (unadjusted and adjusted p-values 0.046 and 0.01,GC50 GCb6 p-value
) 92/454 (20%) 123/453 (27%) 0.007
430 406
98% 83% <0.0001
90%e100% 72%e97%
19%e113% 19%e118%
327 (76%) 146 (36%)
429 423
94% 80%
83e99% 68e94% <0.0001
43e107% 32e106%
260 (61%) 127 (30%)
444 439
100% 100% <0.0001
246 (55%) 281 (64%)
) 133/444 (30%) 263/439 (60%) <0.0001
Table 3
Comparison of treatment arms in terms of key adverse events (i.e. patient-cycle grade 2e4 incidence 10% and/or difference 5%).
Adverse event Grade Patient-cycles with adverse events of the specified
grade
Treated patients with at least one adverse event
of specified grade
GC80
(N Z 1393)
GC50
(N Z 1448)
GCb6
(N Z 1443)
GC80
(N Z 441)
GC50
(N Z 444)
GCb6
(N Z 439)
Nausea 2 262 (19%) 118 (8%) 151 (11%) 161 (37%) 85 (19%) 108 (25%)
3 39 (2.8%) 9 (0.6%) 19 (1.3%) 34 (7.7%) 8 (1.8%) 16 (3.6%)
Vomiting 2 178 (13%) 59 (4%) 77 (5%) 121 (27%) 45 (10%) 58 (13%)
3 34 (2.9%) 3 (0.2%) 12 (0.8%) 29 (6.6%) 2 (0.5%) 10 (2.3%)
Constipation 2 166 (12%) 134 (9%) 144 (10%) 121 (27%) 90 (20%) 101 (23%)
3 5 (0.3%) 5 (0.3%) 5 (0.3%) 5 (1.1%) 5 (1.1%) 5 (1.1%)
Dyspnoea 2 136 (10%) 105 (7%) 180 (13%) 90 (20%) 87 (20%) 119 (27%)
3 24 (1.7%) 27 (1.9%) 29 (2.0%) 23 (5.2%) 25 (5.6%) 23 (5.2%)
Anaemia 2 173 (12%) 154 (11%) 419 (29%) 110 (25%) 103 (23%) 233 (53%)
3 13 (0.9%) 10 (0.7%) 58 (4.0%) 10 (2.3%) 9 (2.0%) 49 (11.2%)
Neutropenia 2 155 (11%) 105 (7%) 384 (27%) 109 (25%) 77 (17%) 238 (54%)
3 74 (5.3%) 49 (3.4%) 227 (15.7%) 60 (13.6%) 40 (9.0%) 163 (37.1%)
Thrombocytopaenia 2 67 (5%) 32 (2%) 213 (15%) 55 (12%) 28 (6%) 138 (31%)
3 32 (2.3%) 13 (0.9%) 144 (10.0%) 29 (6.6%) 12 (2.7%) 103 (23.5%)
Fatigue 2 379 (27%) 326 (23%) 389 (27%) 222 (50%) 193 (43%) 225 (51%)
3 51 (3.7%) 29 (2.0%) 49 (3.4%) 43 (9.8%) 25 (5.6%) 42 (9.6%)
Ototoxicity 2 92 (7%) 44 (3%) 17 (1%) 66 (15%) 28 (6%) 10 (2%)
3 18 (1.3%) 2 (0.1%) 0 (0%) 15 (3.4%) 1 (0.2%) 0 (0%)
Fig. 2. (A)KaplaneMeier survivor functions for each treatment group. (B) Pairwise comparisons of survival showingHRs (adjusted for stage
and performance status) with two-sided 95%CIs (solid line) for assessment of difference (compare either end against HRZ 1) and one-sided
95% CIs (dashed line) for assessment of non-inferiority (compare upper values against HRZ 1.2).
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show that this difference is driven primarily by the inferior
survival of GC50 compared to the other two arms
(adjusted HR for GC50 versus GC80 of 1.13, two-sided
95% CI: 0.99e1.29 and adjusted HR for GC50 versus
GCb6 of 1.23, two-sided 95% CI: 1.08e1.41). Further-
more, GCb6 was found to be significantly non-inferior to
GC80 with adjusted HR Z 0.93 (unadjusted 0.94) and
upper limit of one-sided 95%CI as 1.04 (unadjusted 1.05).
Overall quality of life over time, as measured by the
EQ-5D utility measure (where 0 represents quality
equivalent to death and 1 represents ‘perfect health’) is
relatively constant over time and similar in all three
treatment groups (Fig. 3). Quality-adjusted survival time
shows the same pattern of results across treatment armsas overall survival time (Table 4) with GC50 worst and
GC80 and GCb6 comparable.4. Discussion
This randomised phase III trial compared the effects of
two doses of cisplatin and carboplatin AUC6 in com-
bination with gemcitabine in a treatment naive popula-
tion of patients with advanced NSCLC. The trial was
undertaken in an era before widespread testing for
activating mutations of EGFR and ALK, histological
differentiation and maintenance chemotherapy were
standard practice and the newly introduced immune-
checkpoint inhibitor for tumours with high PD-L1
Table 4
Comparison of survival time and quality-adjusted survival time across treatment arms.
Summary statistic GC80 GC50 GCb6
One year survival rates (95% CIs) 39% (35%e44%) 31% (27%e35%) 39% (34%e43%)
Median survival time in months (95% CIs) 9.5 (8.4e10.3) 8.2 (7.4e8.7) 10.0 (9.2e10.8)
Mean quality-adjusted survival time in months (within 12 months)
(95% CIs)
6.0 (5.7e6.3) 5.6 (5.2e5.9) 6.1 (5.8e6.5)
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relevant for small selected subgroups of patients,
platinum-based combination chemotherapy remains the
standard first-line treatment for the majority of patients
with this disease.
The trial included what could be regarded as the
highest possible safe dose of carboplatin, using the
Wright equation [17] considered to be equivalent to the
Calvert formula [10]. For cisplatin, the trial selected the
highest dose in common use (80 mg/m2) compared with
the lower dose commonly prescribed in the UK (50 mg/
m2). The principal conclusion is that GCb6 is not infe-
rior to GC80 in terms of survival time. This key result
runs counter to all previous meta-analysis [7,26,27]
which concluded cisplatin was superior to carboplatin.
Such analyses have strengths and correctly identified
that cisplatin-based treatment was beneficial in NSCLC,
but they also have limitations, especially when details
such as dose, dose intensity and how doses of carbo-
platin were calculated are significant variables. These
factors could have contributed to decreased effectiveness
of carboplatin in the meta-analysis. This drug has pre-
dominant renal excretion and is no longer prescribed on
a body surface area formula but on the Calvert formula
[10]. Central to using this formula is estimating GFR. In
the original work, 51-Cr-EDTA methodology was used
and widely regarded as the gold standard. However this
can be closely approximated by the Wright formula [17].
This is clearly superior to the CockcrofteGault formula,
which is easy to compute but underestimates GFR by an
average of 10%. Many previous clinical trials allowed
sites to vary the method of GFR estimation or used lowFig. 3. Mean EQ-5D utility score over 12 months (represented as a
step function joining the means of all patients still alive at each
observed death time in the trial).doses such as AUC5 and CockcrofteGault GFR esti-
mation [26]. Having delivered the maximum safe dose of
carboplatin combined with gemcitabine, we found that
this drug is not inferior in survival terms to the highest
reasonable dose of cisplatin (80 mg/m2).
Having conducted the largest ever randomised trial
comparing carboplatin with cisplatin in NSCLC, we
have high resolution adverse event and quality of life
data. When first introduced, cisplatin had a deserved
reputation for often severe emesis, renal damage and
neuropathy [28]. Improvements in anti-emetics, 5-HT3
and NK1 receptor antagonists [29] and better hydration
have attenuated these effects such that although GC80
produced more grade 3e4 vomiting (2.9%) than carbo-
platin (0.8%), the difference is not clinically significant.
Also the trial has enabled a reduction in the hydration
schedule duration for cisplatin, such that it is easy to
deliver cisplatin as a day case. However, carboplatin
does produce worse myelosuppresion, neutropenia and
thrombocytopaenia but with no significant impact on
infections or deaths on treatment. The data on survival,
response rates and toxicity are comparable to other
large randomised trials. In the trial [12] of gemcitabine
plus cisplatin at 75 mg/m2 (GC75) versus pemetrexed
plus cisplatin (PC75) the median survival for GC75 was
10.3 (BTOG2 9.5), response rate was 31% (BTOG2
29%) and febrile neutropenia 3.7% (infection rate 3% in
BTOG2).
In many solid tumours, sequences of chemotherapy
regimens have produced dramatic improvement. The
best example is possibly colorectal cancer where overall
survival has increased over the last 20 years from around
10e12 months to 25e30 months [30]. Instead of only
5FU/folinic acid these patients have combinations of
5FU, oxalipaltin and irinotecan often combined with the
antiangiogenic bevacizumab. To RAS wild type pa-
tients, anti-EGFR antibodies are also given. NSCLC
has been slower to develop sequential therapy, but for
adenocarcinoma patients maintenance therapy with
pemetrexed immediately after first line cisplatin-
gemcitabine and taxanes after carboplatin-gemcitabine
were each shown to be beneficial. The recent
KEYNOTE-024 trial [16], which included comparable
patients to BTOG2 including both squamous and non-
squamous histologies and selected for high expression
of PD-L1, demonstrated that the immune-checkpoint
inhibitor pembrolizumab improves progression-free
survival time and overall survival time in the first-line
setting in comparison to chemotherapy and may become
Research in context
Evidence before this study
Platinum-based combination chemotherapy was firmly
established as the standard first-line treatment for patients
with advanced NSCLC following a meta-analysis of eight
randomised trials but clinical practice varied regarding the
choice and dose of platinum agent. The evidence on
whether cisplatin or carboplatin gave better patient out-
comes was ambiguous and following an influential trial
there was a move towards the greater use of carboplatin,
despite a meta-analysis demonstrating superiority of
cisplatin. In addition for those choosing cisplatin, there
was uncertainty regarding the dose, with practitioners in
the United Kingdom often opting for a lower dose than
counterparts in Europe and the United States.
Added value of this study
This large randomised phase III trial provides the
D. Ferry et al. / European Journal of Cancer 83 (2017) 302e312310the first-line treatment of choice for selected patients. Of
the 1934 patients screened, 1653 had samples that could
be evaluated for PD-L1, 500 (30%) had high expression
and 305 were randomised into the trial demonstrating
that this treatment was an option for only 15% of the
screened population. Because patients are not cured by
first-line checkpoint inhibitors, for those who are eligible
for this option, it is important that optimal platinum-
based combination chemotherapy follows to produce
best results for patients. This illustrates that chemo-
therapy practice and principles will remain the same, but
sequencing for some may change. Optimising all aspects
of anti-cancer treatments is essential, especially the
doses and schedules of chemotherapy drugs which may
impact survival and the BTOG2 trial contributes
important data in this regard.
In summary, the BTOG2 trial provides definitive
evidence on the choice of platinum to partner with a
second drug in standard first-line chemotherapy for
advanced NSCLC and provides for the first time
comprehensive quality of life data to support decision-
making. Carboplatin dosed at AUC6 using the Wright
equation (or Calvert equation) gives non-inferior sur-
vival to cisplatin dosed at 80 mg/m2 and cisplatin at the
lower dose of 50 mg/m2 has worse survival which is not
compensated by better quality of life.
definitive evidence-base for the choice of platinum in
standard first-line combination chemotherapy for
advanced NSCLC. It establishes conclusively that the
lower dose of 50 mg/m2 of cisplatin commonly used in
the United Kingdom gives inferior survival outcomes
which are not compensated by better quality of life. It
also clarifies that carboplatin delivered at a dose of
AUC6 is not inferior to cisplatin at 80 mg/m2 in terms ofFunding
Funding was from Cancer Research UK supple-
mented by an educational grant from Eli Lilly and
Company Ltd. The trial was initiated and conducted
independently by the trial investigators.
survival time. In addition carboplatin unexpectedly was
associated with significantly more adverse events and
not associated with better quality of life.
Implications of all the available evidence
Platinum-based combination chemotherapy remains the
standard first-line treatment for the majority of patients
with advanced NSCLC. Although patients with EGFR
mutations, ALK gene rearrangements or high PDL1
expression can now receive targeted treatments, this only
affects a minority of patients (approximately 8%, 2%
and 15%, respectively in the UK). Taken together with
previous studies, the BTOG2 trial shows that carbo-
platin AUC6 and cisplatin 80 mg/m2 offer comparable
survival benefits in advanced NSCLC, but a lower dose
of cisplatin is inferior. In choosing between these two
superior options, the burden of adverse events related to
carboplatin should not be underestimated and better
quality of life associated with carboplatin should not be
assumed. Therefore, in patients for whom a targeted
treatment is not available, platinum-based combination
chemotherapy should be considered with either carbo-
platin AUC6 or cisplatin 80 mg/m2.Conflict of interest statement
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